Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection.

Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ.

HIV Clin Trials. 2018 Jun;19(3):85-93. doi: 10.1080/15284336.2018.1452842. Epub 2018 Apr 20.

PMID:
29676212
2.

Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kang YK, Arrigale RR, Donovan GP, Magargal WW, Maddon PJ, Olson WC.

J Infect Dis. 2012 Sep 1;206(5):706-13. doi: 10.1093/infdis/jis416. Epub 2012 Jun 25.

3.

Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.

Coburn GA, Fisch DN, Moorji SM, de Muys JM, Murga JD, Paul D, Provoncha KP, Rotshteyn Y, Han AQ, Qian D, Maddon PJ, Olson WC.

PLoS One. 2012;7(4):e35351. doi: 10.1371/journal.pone.0035351. Epub 2012 Apr 24.

4.

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26.

5.

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.

6.

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Kang YK, Andjelic S, Binley JM, Crooks ET, Franti M, Iyer SP, Donovan GP, Dey AK, Zhu P, Roux KH, Durso RJ, Parsons TF, Maddon PJ, Moore JP, Olson WC.

Vaccine. 2009 Aug 13;27(37):5120-32. doi: 10.1016/j.vaccine.2009.06.037. Epub 2009 Jun 28.

7.

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC.

J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169.

PMID:
18771406
8.

A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.

Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR, Wang X, Maughan MF, Talarico TL, Olmsted RA, Heston WD, Maddon PJ, Olson WC.

Clin Cancer Res. 2007 Jul 1;13(13):3999-4008.

9.

Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers.

Iyer SP, Franti M, Krauchuk AA, Fisch DN, Ouattara AA, Roux KH, Krawiec L, Dey AK, Beddows S, Maddon PJ, Moore JP, Olson WC.

AIDS Res Hum Retroviruses. 2007 Jun;23(6):817-28.

PMID:
17604546
10.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.

11.

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC.

Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96.

12.

L-SIGN (CD209L) isoforms differently mediate trans-infection of hepatoma cells by hepatitis C virus pseudoparticles.

Falkowska E, Durso RJ, Gardner JP, Cormier EG, Arrigale RA, Ogawa RN, Donovan GP, Maddon PJ, Olson WC, Dragic T.

J Gen Virol. 2006 Sep;87(Pt 9):2571-6.

PMID:
16894195
13.

Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A.

Beddows S, Kirschner M, Campbell-Gardener L, Franti M, Dey AK, Iyer SP, Maddon PJ, Paluch M, Master A, Overbaugh J, VanCott T, Olson WC, Moore JP.

AIDS Res Hum Retroviruses. 2006 Jun;22(6):569-79.

PMID:
16796532
14.

Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.

Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, Olson WC.

Clin Cancer Res. 2006 Apr 15;12(8):2591-6.

15.

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Beddows S, Schülke N, Kirschner M, Barnes K, Franti M, Michael E, Ketas T, Sanders RW, Maddon PJ, Olson WC, Moore JP.

J Virol. 2005 Jul;79(14):8812-27.

16.

Resistance to HIV-1 entry inhibitors.

Olson WC, Maddon PJ.

Curr Drug Targets Infect Disord. 2003 Dec;3(4):283-94. Review.

PMID:
14754430
17.

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC.

Antimicrob Agents Chemother. 2004 Feb;48(2):423-9.

18.

The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.

Schülke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD, Olson WC.

Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12590-5.

19.

L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus.

Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4498-503. Epub 2003 Apr 3.

20.

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP.

J Virol. 2002 Sep;76(17):8875-89.

21.

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.

Schülke N, Vesanen MS, Sanders RW, Zhu P, Lu M, Anselma DJ, Villa AR, Parren PW, Binley JM, Roux KH, Maddon PJ, Moore JP, Olson WC.

J Virol. 2002 Aug;76(15):7760-76.

22.

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.

Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC.

J Infect Dis. 2001 Apr 1;183(7):1121-5. Epub 2001 Mar 8.

PMID:
11237840
23.

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC.

J Virol. 2001 Jan;75(2):579-88.

24.

Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.

Shearer WT, Israel RJ, Starr S, Fletcher CV, Wara D, Rathore M, Church J, DeVille J, Fenton T, Graham B, Samson P, Staprans S, McNamara J, Moye J, Maddon PJ, Olson WC.

J Infect Dis. 2000 Dec;182(6):1774-9. Epub 2000 Oct 27.

PMID:
11069253
25.

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.

Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, Trkola A, Klotman ME, Maddon PJ, Olson WC, Israel RJ.

J Infect Dis. 2000 Jul;182(1):326-9. Epub 2000 Jun 30.

PMID:
10882617
26.
27.

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T.

J Virol. 1999 May;73(5):4145-55.

28.

CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates.

Gauduin MC, Allaway GP, Olson WC, Weir R, Maddon PJ, Koup RA.

J Virol. 1998 Apr;72(4):3475-8.

29.

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP.

Nat Med. 1998 Jan;4(1):72-7.

PMID:
9427609
30.

Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.

Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP, Sakmar TP, Moore JP, Maddon PJ.

J Virol. 1998 Jan;72(1):279-85.

31.

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP.

Nature. 1996 Nov 14;384(6605):184-7.

PMID:
8906796
32.

Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer.

Litwin V, Nagashima KA, Ryder AM, Chang CH, Carver JM, Olson WC, Alizon M, Hasel KW, Maddon PJ, Allaway GP.

J Virol. 1996 Sep;70(9):6437-41.

33.

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA.

Nature. 1996 Jun 20;381(6584):667-73.

PMID:
8649512
34.

Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.

Gauduin MC, Allaway GP, Maddon PJ, Barbas CF 3rd, Burton DR, Koup RA.

J Virol. 1996 Apr;70(4):2586-92.

35.

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF 3rd, Burton DR, Ho DD, et al.

J Virol. 1995 Nov;69(11):6609-17.

36.
37.

Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.

Allaway GP, Ryder AM, Beaudry GA, Maddon PJ.

AIDS Res Hum Retroviruses. 1993 Jul;9(7):581-7.

PMID:
8369162
39.
40.

Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity.

Kennedy MS, Orloff S, Ibegbu CC, Odell CD, Maddon PJ, McDougal JS.

AIDS Res Hum Retroviruses. 1991 Dec;7(12):975-81.

PMID:
1687500
41.

CD4-gp120 interactions.

McDougal JS, Klatzmann DR, Maddon PJ.

Curr Opin Immunol. 1991 Aug;3(4):552-8. Review.

PMID:
1721822
42.
43.

Role of CD4 in the penetration of cells by HIV.

McDougal JS, Maddon PJ, Orloff G, Clapham PR, Dalgleish AG, Jamal S, Weiss RA, Axel RA.

Adv Exp Med Biol. 1991;300:145-54; discussion 155-8. No abstract available.

PMID:
1685856
44.

The CD4 molecule and HIV infection.

Klatzmann DR, McDougal JS, Maddon PJ.

Immunodefic Rev. 1990;2(1):43-66. Review.

PMID:
1973616
45.

Structural features of CD4 required for binding to HIV.

Ibegbu CC, Kennedy MS, Maddon PJ, Deen KC, Hicks D, Sweet RW, McDougal JS.

J Immunol. 1989 Apr 1;142(7):2250-6.

PMID:
2538505
46.

Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.

Clapham PR, Weber JN, Whitby D, McIntosh K, Dalgleish AG, Maddon PJ, Deen KC, Sweet RW, Weiss RA.

Nature. 1989 Jan 26;337(6205):368-70.

PMID:
2536142
47.

Corrected CD4 sequence.

Littman DR, Maddon PJ, Axel R.

Cell. 1988 Nov 18;55(4):541. No abstract available.

PMID:
3263213
48.

HIV infection does not require endocytosis of its receptor, CD4.

Maddon PJ, McDougal JS, Clapham PR, Dalgleish AG, Jamal S, Weiss RA, Axel R.

Cell. 1988 Sep 9;54(6):865-74.

PMID:
3261635
49.

Infection of B lymphocytes by the human immunodeficiency virus and their susceptibility to cytotoxic cells.

Malkovský M, Philpott K, Dalgleish AG, Mellor AL, Patterson S, Webster AD, Edwards AJ, Maddon PJ.

Eur J Immunol. 1988 Sep;18(9):1315-21.

PMID:
2901961
50.

A soluble form of CD4 (T4) protein inhibits AIDS virus infection.

Deen KC, McDougal JS, Inacker R, Folena-Wasserman G, Arthos J, Rosenberg J, Maddon PJ, Axel R, Sweet RW.

Nature. 1988 Jan 7;331(6151):82-4.

PMID:
3257544

Supplemental Content

Loading ...
Support Center